{"id":"https://openalex.org/W612392283","doi":"https://doi.org/10.1200/jco.2006.24.18_suppl.2015","title":"Phase I trial of CT-2106 (polyglutamated camptothecin) administered weekly in patients (pts) with advanced solid tumors","display_name":"Phase I trial of CT-2106 (polyglutamated camptothecin) administered weekly in patients (pts) with advanced solid tumors","publication_year":2006,"publication_date":"2006-06-20","ids":{"openalex":"https://openalex.org/W612392283","doi":"https://doi.org/10.1200/jco.2006.24.18_suppl.2015","mag":"612392283"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2006.24.18_suppl.2015","doi":"https://doi.org/10.1200/jco.2006.24.18_suppl.2015","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2006.24.18_suppl.2015","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018322482","display_name":"ADIL I. DAUD","orcid":"https://orcid.org/0000-0002-6617-8421","observed_orcids":["https://orcid.org/0000-0002-6617-8421"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Daud","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL; Cell Therapeutics, Inc., Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL; Cell Therapeutics, Inc., Seattle, WA","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049076838","display_name":"Chris R. Garrett","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Garrett","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL; Cell Therapeutics, Inc., Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL; Cell Therapeutics, Inc., Seattle, WA","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102964486","display_name":"George R. Simon","orcid":"https://orcid.org/0000-0002-3894-0773","observed_orcids":["https://orcid.org/0000-0002-3894-0773"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G. R. Simon","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL; Cell Therapeutics, Inc., Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL; Cell Therapeutics, Inc., Seattle, WA","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083373965","display_name":"Pamela N. M\u00fcnster","orcid":"https://orcid.org/0000-0002-2074-0984","observed_orcids":["https://orcid.org/0000-0002-2074-0984","https://orcid.org/0009-0009-4141-2312"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. Munster","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL; Cell Therapeutics, Inc., Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL; Cell Therapeutics, Inc., Seattle, WA","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102841436","display_name":"Daniel M. Sullivan","orcid":"https://orcid.org/0009-0003-0951-9781","observed_orcids":["https://orcid.org/0009-0003-0951-9781","https://orcid.org/0000-0002-2183-1773"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Sullivan","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL; Cell Therapeutics, Inc., Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL; Cell Therapeutics, Inc., Seattle, WA","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078642863","display_name":"Scott C. Stromatt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Stromatt","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL; Cell Therapeutics, Inc., Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL; Cell Therapeutics, Inc., Seattle, WA","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004376783","display_name":"C. Allevi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Allevi","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL; Cell Therapeutics, Inc., Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL; Cell Therapeutics, Inc., Seattle, WA","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5066626291","display_name":"B. Bernareggi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"B. Bernareggi","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL; Cell Therapeutics, Inc., Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL; Cell Therapeutics, Inc., Seattle, WA","institution_ids":["https://openalex.org/I3019308854"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I3019308854"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":11,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"24","issue":"18_suppl","first_page":"2015","last_page":"2015"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12356","display_name":"Bioactive Compounds and Antitumor Agents","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/topoisomerase-i-inhibitor","display_name":"topoisomerase I inhibitor","score":0.9909999966621399},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.824999988079071},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.9570000171661377},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8820000290870667},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9729999899864197},{"id":"https://openalex.org/keywords/polymeric-drug-delivery","display_name":"polymeric drug delivery","score":0.6940000057220459},{"id":"https://openalex.org/keywords/once-weekly-dosing","display_name":"weekly dosing","score":0.7300000190734863},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.6629999876022339},{"id":"https://openalex.org/keywords/drug-accumulation","display_name":"drug accumulation","score":0.3100000023841858},{"id":"https://openalex.org/keywords/renal-excretion","display_name":"renal excretion","score":0.8159999847412109},{"id":"https://openalex.org/keywords/hemorrhagic-cystitis","display_name":"hemorrhagic cystitis","score":0.7020000219345093},{"id":"https://openalex.org/keywords/diarrhea","display_name":"diarrhea","score":0.8119999766349792},{"id":"https://openalex.org/keywords/tumor-response","display_name":"tumor response","score":0.4519999921321869}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7556480765342712},{"id":"https://openalex.org/C2779682216","wikidata":"https://www.wikidata.org/wiki/Q419964","display_name":"Camptothecin","level":2,"score":0.647995114326477},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6353969573974609},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5581665635108948},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.46805399656295776},{"id":"https://openalex.org/C10146269","wikidata":"https://www.wikidata.org/wiki/Q185557","display_name":"Excretion","level":2,"score":0.4107241928577423},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3689519762992859},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3469642996788025},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.21490374207496643},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.11675474047660828}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2006.24.18_suppl.2015","doi":"https://doi.org/10.1200/jco.2006.24.18_suppl.2015","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2006.24.18_suppl.2015","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2165164305","https://openalex.org/W2240322050","https://openalex.org/W2604389513","https://openalex.org/W2139550132","https://openalex.org/W2065816581","https://openalex.org/W2325203971","https://openalex.org/W2588256758","https://openalex.org/W2169509935","https://openalex.org/W2252960448","https://openalex.org/W2049372134"],"abstract_inverted_index":{"2015":[0],"Background:":[1],"CT-2106,":[2],"a":[3,8,22,49,171],"camptothecin":[4],"(CPT)":[5],"conjugate,":[6],"is":[7,131,206,218,277,296],"topoisomerase":[9],"I":[10],"inhibitor.":[11],"Covalent":[12],"binding":[13,42],"through":[14],"the":[15,36,56,71,144,198,209,282],"hydroxyl":[16],"group":[17],"of":[18,25,35,65,76,99,176,194,203,212,224,253],"CPT":[19,29,41,121,180,189,196,205,216,226,247,257],"to":[20,43,69,80,187,228,231],"polyglutamate,":[21],"biodegradable":[23],"polymer":[24],"glutamic":[26],"acid,":[27],"enhances":[28],"aqueous":[30],"solubility":[31],"and":[32,39,73,97,108,119,125,178,190,246,291],"prevents":[33],"opening":[34],"lactone":[37],"ring":[38],"subsequent":[40],"albumin.":[44],"Responses":[45],"were":[46,112],"observed":[47,260],"in":[48,54,143,267,299],"Q3":[50,172,263],"week":[51,173,264],"dosing":[52,270],"study":[53,67,174,271],"which":[55],"maximum":[57],"tolerated":[58,280],"dose":[59],"(MTD)":[60],"was":[61,115,258],"75":[62],"mg/m2.":[63],"Objectives":[64],"this":[66,268],"are":[68,141],"determine":[70],"MTD":[72,295],"pharmacokinetics":[74],"(PK)":[75],"CT-2106":[77,88,183,276],"given":[78],"weekly":[79,269],"pts":[81,166],"with":[82,133,261,286],"advanced":[83],"cancer.":[84],"Methods:":[85],"Pts":[86],"received":[87],"(10":[89],"min":[90],"IV":[91],"infusion)":[92],"on":[93,208],"days":[94],"1,":[95],"8,":[96],"15":[98],"each":[100],"28":[101],"day":[102],"cycle.":[103],"Toxicity":[104],"(NCI":[105],"CTC":[106],"v3)":[107],"tumor":[109],"response":[110],"(RECIST)":[111],"assessed.":[113],"Plasma":[114],"analyzed":[116],"for":[117],"conjugated":[118,177,188,213,225,254],"unconjugated":[120,179,204,215,256],"by":[122,241],"liquid":[123],"chromatography":[124],"tandem":[126],"mass":[127],"spectrometry.":[128],"Results:":[129],"Enrollment":[130],"complete":[132],"21":[134],"evualuable":[135],"pts.":[136,303],"Dose":[137],"limiting":[138],"toxicities":[139,283],"(DLT)":[140],"shown":[142],"table":[145],".":[146],"Median":[147],"age":[148],"=":[149,156,162],"60":[150],"years":[151],"(range":[152],"36\u201383),":[153],"median":[154,159],"doses":[155],"6":[157],"(1\u20139),":[158],"prior":[160],"therapies":[161],"3":[163],"(1\u20136).":[164],"Most":[165],"(12)":[167],"had":[168],"melanoma.":[169],"In":[170],"assessments":[175],"demonstrated":[181],"that":[182],"provides":[184],"prolonged":[185],"exposure":[186],"slow,":[191],"progressive":[192],"release":[193],"active":[195],"from":[197],"polymeric":[199],"backbone.":[200],"The":[201,222,294],"PK":[202,266],"dependent":[207],"disposition":[210],"profile":[211],"CPT;":[214],"elimination":[217],"formation":[219],"rate":[220],"limited.":[221],"distribution":[223],"appears":[227],"be":[229,273],"restricted":[230],"extracellular":[232],"body":[233],"fluids.":[234],"Total":[235],"clearance":[236],"includes":[237],"renal":[238],"excretion":[239,244],"documented":[240],"substantial":[242],"urinary":[243],"levels":[245],"cleavage":[248],"via":[249],"metabolic":[250],"pathways.":[251],"Accumulation":[252],"or":[255],"not":[259],"repeated":[262],"dosing.":[265],"will":[272],"presented.":[274],"Conclusions:":[275],"generally":[278],"well":[279],"without":[281],"normally":[284],"associated":[285],"CPT,":[287],"specifically":[288],"hemorrhagic":[289],"cystitis":[290],"severe":[292],"diarrhea.":[293],"25\u201335":[297],"mg/m2":[298],"these":[300],"heavily":[301],"pretreated":[302],"[Table:":[304,307],"see":[305,308],"text]":[306,309]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2016-06-24T00:00:00"}